Investigation-directed approach to inflammatory optic neuropathies

Seminars in Ophthalmology

Volumn 31, Issue 1-2, 2016, Pages 117-130

  Boudreault, Katherine ^a   Durand, Marlene L ^a   Rizzo, Joseph F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atypical optic neuritis; Lupus; Lyme borreliosis; Myelin oligodendrocyte glycoprotein (MOG); Neuromyelitis optica (NMO); Sarcoidosis

Indexed keywords

ALPHA INTERFERON; ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; FINGOLIMOD; NATALIZUMAB; RITUXIMAB;

CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEMYELINATING DISEASE; DEMYELINATIVE OPTIC NEURITIS; DIFFERENTIAL DIAGNOSIS; EYE BIOPSY; EYE EXAMINATION; FLUORESCENCE ANGIOGRAPHY; GLAUCOMA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS OPTIC NEUROPATHY; LYME DISEASE; LYME OPTIC NEUROPATHY; MYELOOPTIC NEUROPATHY; NEUROSYPHILIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PARANEOPLASTIC NEUROPATHY; PARANEOPLASTIC OPTIC NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SARCOID OPTIC NEUROPATHY; SARCOIDOSIS; SYPHILITIC OPTIC NEUROPATHY; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSLATIONAL RESEARCH; CHEMICALLY INDUCED; COMPLICATION; LYME NEUROBORRELIOSIS; NEUROMYELITIS OPTICA;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LYME NEUROBORRELIOSIS; NEUROMYELITIS OPTICA; NEUROSYPHILIS; OPTIC NEURITIS; SARCOIDOSIS;

EID: 84962159919     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2015.1114835     Document Type: Review

References (111)

1. Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Archives of Ophthalmology 1991;109(12):1673-1678.
2. Warner JE, Lessell S, Rizzo 3rd JF, Newman NJ. Does optic disc appearance distinguish ischemic optic neuropathy from optic neuritis? Archives of Ophthalmology 1997; 115(11):1408-1410.
3. Rizzo 3rd JF, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002;109(9):1679-1684.
4. Liu GT, Volpe NJ, Galetta SL. Neuro-Ophthalmology: Diagnosis and Management, 2nd ed.; Philadelphia: W. B. Saunders, 2001.
5. Rizzo 3rd JF, Lessell S. Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles. Archives of Ophthalmology 1991;109(12):1668-1672.
6. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101(11):1771-1778.
7. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: A final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082 e5.
8. Rizzo 3rd JF, Lessell S. Risk of developing multiple sclerosis after uncomplicated optic neuritis: A long-term prospective study. Neurology 1988;38(2):185-190.
9. Fazzone HE, Lefton DR, Kupersmith MJ. Optic neuritis: correlation of pain and magnetic resonance imaging. Ophthalmology 2003;110(8):1646-1649.
10. Allbutt TC. On the ophthalmoscopic signs of spinal disease. Lancet 1870;95(2420):76-78.
11. Devic E. Myélite aiguëdorso-lombaire avec névrite optique, autopsie. In: Congrès français de médecine, Première Session, Lyon 1894. Procès-verbaux, mémoires et discussions. Asselin&Houzeau, Paris; Louis Savy, Lyon 1985:434-439.
12. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106-2112.
13. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. Neurology 2012;78(9):665-671; discussion 9.
14. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66(10):1485-1489.
15. Vaknin-Dembinsky A, Karussis D, Avichzer J, Abramsky O. NMO spectrum of disorders: A paradigm for astrocytetargeting autoimmunity and its implications for MS and other CNS inflammatory diseases. Journal of Autoimmunity 2014;54:93-99.
16. Jarius S, Franciotta D, Paul F, et al. Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. Journal of Neuroinflammation 2010;7:52.
17. Sato DK, Lana-Peixoto MA, Fujihara K, de Seze J. Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status. Brain Pathol 2013; 23(6):647-660.
18. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: A consensus approach. Mult Scler 2008;14(9):1157-1174.
19. Papais-Alvarenga RM, Carellos SC, Alvarenga MP, et al. Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Archives of Ophthalmology 2008; 126(1):12-16.
20. Merle H, Olindo S, Bonnan M, et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 2007;114(4):810-815.
21. Pirko I, Blauwet LA, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Archives of Neurology 2004;61(9):1401-1405.
22. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53(5):1107-1114.
23. Jarius S, Frederikson J, Waters P, et al. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences 2010; 298(1-2):158-162.
24. Etemadifar M, Abtahi MA, Razmjoo H, et al. Antiaquaporin-4 IgG in patients presenting with unilateral optic neuritis: A cohort study. International Journal of Preventive Medicine 2012;3(9):612-615.
25. Galetta SL, Cornblath WT. Should most patients with optic neuritis be tested for neuromyelitis optica antibodies and should this affect their treatment? Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society 2010;30(4):376-378; discussion 8-9.
26. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation 2012;9:14.
27. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibodypositive NMO spectrum disorders. Neurology 2014; 82(6):474-481.
28. Kezuka T, Usui Y, Yamakawa N, et al. Relationship between NMO-antibody and anti-MOG antibody in optic neuritis. Journal of Neuro-Ophthalmology: The Official Journal of the North American Neuro-Ophthalmology Society 2012; 32(2):107-110.
29. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurology 2014;71(3):276-283.
30. Hoftberger R, Sepulveda M, Armangue T, et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 2014; 21(7):866-874.
31. Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurology(R) Neuroimmunology&Neuroinflammation 2014;1(4):e40.
32. Nakajima H, Motomura M, Tanaka K, et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis. BMJ Open 2015;5(4):e007766.
33. Ikeda K, Kiyota N, Kuroda H, et al. Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. Mult Scler 2015;21(5):656-659.
34. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurology(R) Neuroimmunology&Neuroinflammation 2015;2(1):e62.
35. Sakuma H, Kohyama K, Park IK, et al. Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW. 1AV1 rats. Brain: A Journal of Neurology 2004;127(Pt 10):2201-2213.
36. Trebst C, Jarius S, Berthele A, et al. Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology 2014;261(1):1-16.
37. Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Archives of Neurology 2010; 67(8):1016-1017.
38. Barnett MH, Prineas JW, Buckland ME, et al. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012;18(1):108-112.
39. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. Journal of Neurology, Neurosurgery, and Psychiatry 2010;81(1):109-111.
40. Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: A systematic review of 122 cases reported. Journal of Neurology 2014;261(1):17-26.
41. Jabs DA, Miller NR, Newman SA, et al. Optic neuropathy in systemic lupus erythematosus. Archives of Ophthalmology 1986;104(4):564-568.
42. Lin YC, Wang AG, Yen MY. Systemic lupus erythematosusassociated optic neuritis: clinical experience and literature review. Acta Ophthalmologica 2009;87(2):204-210.
43. Frigui M, Frikha F, Sellemi D, et al. Optic neuropathy as a presenting feature of systemic lupus erythematosus: Two case reports and literature review. Lupus 2011; 20(11):1214-1218.
44. Colglazier CL, Sutej PG. Laboratory testing in the rheumatic diseases: A practical review. Southern Medical Journal 2005;98(2):185-191.
45. Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: A journey revisited. Diagnostic Pathology 2009;4:1.
46. Rahman A, Isenberg DA. Systemic lupus erythematosus. The New England Journal of Medicine 2008; 358(9):929-939.
47. Wichainun R, Kasitanon N, Wangkaew S, et al. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: A comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pacific Journal of Allergy and Immunology 2013;31(4):292-298.
48. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. The New England Journal of Medicine 2003;349(16):1526-1533.
49. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism 2012; 64(8):2677-2686.
50. Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clinical Rheumatology 1999;18(2):124-131.
51. Tozzoli R, Bizzaro N, Tonutti E, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. American Journal of Clinical Pathology 2002;117(2):316-324.
52. Frohman L, Dellatorre K, Turbin R, Bielory L. Clinical characteristics, diagnostic criteria and therapeutic outcomes in autoimmune optic neuropathy. The British Journal of Ophthalmology 2009;93(12):1660-1666.
53. Kupersmith MJ, Burde RM, Warren FA, et al. Autoimmune optic neuropathy: evaluation and treatment. Journal of Neurology, Neurosurgery, and Psychiatry 1988; 51(11):1381-1386.
54. Riedel P, Wall M, Grey A, et al. Autoimmune optic neuropathy. Archives of Ophthalmology 1998;116(8): 1121-1124.
55. Reich A, Marcinow K, Bialynicki-Birula R. The lupus band test in systemic lupus erythematosus patients. Therapeutics and Clinical Risk Management 2011;7:27-32.
56. Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Annals of Neurology 2003;54(1):38-50.
57. Chan JW. Paraneoplastic retinopathies and optic neuropathies. Survey of Ophthalmology 2003;48(1):12-38.
58. Rahimy E, Sarraf D. Paraneoplastic and non-paraneoplastic retinopathy and optic neuropathy: evaluation and management. Survey of Ophthalmology 2013;58(5):430-458.
59. Yang HK, Woo SJ, Park WY, Hwang JM. Paraneoplastic neuromyelitis optica associated with ANNA-1 antibodies in invasive thymoma. BMC Ophthalmology 2014;14:106.
60. Chamberlain MC. Neoplastic meningitis. The Oncologist 2008;13(9):967-977.
61. Yu Z, Kryzer TJ, Griesmann GE, Kim K, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Annals of Neurology 2001; 49(2):146-154.
62. Valeyre D, Chapelon-Abric C, Belin C, Dumas JL. [Sarcoidosis of the central nervous system]. La Revue de Medecine Interne 1998;19(6):409-414.
63. Hebel R, Dubaniewicz-Wybieralska M, Dubaniewicz A. Overview of neurosarcoidosis: recent advances. Journal of Neurology 2015;262(2):258-267.
64. Koczman JJ, Rouleau J, Gaunt M, et al. Neuro-ophthalmic sarcoidosis: The University of Iowa experience. Seminars in Ophthalmology 2008;23(3):157-168.
65. Lamirel C, Badelon I, Gout O, et al. [Neuro-ophthalmologic initial presentation of sarcoidosis]. Journal Francais d'Ophtalmologie 2006;29(3):241-249.
66. Heuser K, Kerty E. Neuro-ophthalmological findings in sarcoidosis. Acta Ophthalmologica Scandinavica 2004; 82(6):723-729.
67. Castagna I, Salmeri G, Fama F, et al. Optic nerve granuloma as first sign of systemic sarcoidosis. Ophthalmologica Journal International d'Ophtalmologie 1994;208(4):230-232.
68. Mafee MF, Dorodi S, Pai E. Sarcoidosis of the eye, orbit, and central nervous system: role of MR imaging. Radiologic Clinics of North America 1999;37(1):73-87.
69. Pollock JM, Greiner FG, Crowder JB, et al. Neurosarcoidosis mimicking a malignant optic glioma. Journal of Neuro-Ophthalmology 2008;28(3):214-216.
70. Beneteau-Burnat B, Baudin B. Angiotensin-converting enzyme: clinical applications and laboratory investigations on serum and other biological fluids. Critical Reviews in Clinical Laboratory Sciences 1991; 28(5-6):337-356.
71. Herbort CP, Rao NA, Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocular Immunology and Inflammation 2009;17(3):160-169.
72. Beardsley TL, Brown SV, Sydnor CF, et al. Eleven cases of sarcoidosis of the optic nerve. American Journal of Ophthalmology 1984;97(1):62-77.
73. Sharma OP. Vitamin D, calcium, and sarcoidosis. Chest 1996;109(2):535-539.
74. Cremers J, Drent M, Driessen A, et al. Liver-test abnormalities in sarcoidosis. European Journal of Gastroenterology&Hepatology 2012;24(1):17-24.
75. Frohman LP, Grigorian R, Bielory L. Neuro-ophthalmic manifestations of sarcoidosis: clinical spectrum, evaluation, and management. Journal of Neuro-Ophthalmology 2001;21(2):132-137.
76. Frohman LP, Guirgis M, Turbin RE, Bielory L. Sarcoidosis of the anterior visual pathway: 24 new cases. Journal of Neuro-Ophthalmology 2003;23(3):190-197.
77. Nowak DA, Widenka DC. Neurosarcoidosis: A review of its intracranial manifestation. Journal of Neurology 2001; 248(5):363-372.
78. Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Seminars in Ophthalmology 2005; 20(3):161-167.
79. Browning DJ. Posterior segment manifestations of active ocular syphilis, their response to a neurosyphilis regimen of penicillin therapy, and the influence of human immunodeficiency virus status on response. Ophthalmology 2000; 107(11):2015-2023.
80. Chao JR, Khurana RN, Fawzi AA, et al. Syphilis: reemergence of an old adversary. Ophthalmology 2006; 113(11):2074-2079.
81. Puech C, Gennai S, Pavese P, et al. Ocular manifestations of syphilis: recent cases over a 2. 5-year period. Graefe's Archive for Clinical and Experimental Ophthalmology 2010; 248(11):1623-1629.
82. Bandettini di Poggio M, Primavera A, Capello E, et al. A case of secondary syphilis presenting as optic neuritis. Neurological Sciences 2010;31(3):365-367.
83. Weinstein JM, Lexow SS, Ho P, Spickards A. Acute syphilitic optic neuritis. Archives of Ophthalmology 1981; 99(8):1392-1395.
84. Danesh-Meyer H, Kubis KC, Sergott RC. Not so slowly progressive visual loss. Survey of Ophthalmology 1999; 44(3):247-252.
85. Meehan K, Rodman J. Ocular perineuritis secondary to neurosyphilis. Optometry and Vision Science 2010; 87(10):E790-796.
86. Ghanem KG. Neurosyphilis: A historical perspective and review. CNS Neuroscience&Therapeutics 2010; 16(5):e157-168.
87. Smith GT, Goldmeier D, Migdal C. Neurosyphilis with optic neuritis: An update. Postgraduate Medical Journal 2006; 82(963):36-39.
88. Schlaegel Jr TF, Kao SF. A review (1970-1980) of 28 presumptive cases of syphilitic uveitis. American Journal of Ophthalmology 1982;93(4):412-414.
89. Tamesis RR, Foster CS. Ocular syphilis. Ophthalmology 1990;97(10):1281-1287.
90. Margo CE, Hamed LM. Ocular syphilis. Survey of Ophthalmology 1992;37(3):203-220.
91. Blanc F, Ballonzoli L, Marcel C, et al. Lyme optic neuritis. Journal of the Neurological Sciences 2010; 295(1-2):117-119.
92. Stricker RB, Lautin A. Lyme disease and optic neuritis: long-term follow-up of seropositive patients. Neurology 2003;61(8):1162; author reply 3.
93. Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. Journal of Neuro-Ophthalmology 2005;25(2):71-82.
94. Krim E, Guehl D, Burbaud P, Lagueny A. Retrobulbar optic neuritis: A complication of Lyme disease? Journal of Neurology, Neurosurgery, and Psychiatry 2007; 78(12):1409-1410.
95. Sood SK. Lyme disease in children. Infectious Disease Clinics of North America 2015;29(2):281-294.
96. Steere AC, Berardi VP, Weeks KE, et al. Evaluation of the intrathecal antibody response to Borrelia burgdorferi as a diagnostic test for Lyme neuroborreliosis. The Journal of Infectious Diseases 1990;161(6):1203-1209.
97. Hansen K, Crone C, Kristoferitsch W. Lyme neuroborreliosis. Handbook of Clinical Neurology, Peripheral Nerve Disorders; Amsterdam: Elsevier, 2013; 559-75.
98. Halperin JJ. Nervous system lyme disease. Infectious Disease Clinics of North America 2015;29(2):241-253.
99. Rupprecht TA, Koedel U, Fingerle V, Pfister HW. The pathogenesis of lyme neuroborreliosis: from infection to inflammation. Mol Med 2008;14(3-4):205-212.
100. Cadavid D, O'Neill T, Schaefer H, Pachner AR. Localization of Borrelia burgdorferi in the nervous system and other organs in a nonhuman primate model of Lyme disease. Laboratory Investigation 2000;80(7):1043-1054.
101. Pachner AR, Steiner I. Lyme neuroborreliosis: infection, immunity, and inflammation. The Lancet Neurology 2007; 6(6):544-552.
102. Seriburi V, Ndukwe N, Chang Z, et al. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clinical Microbiology and Infection 2012; 18(12):1236-1240.
103. Kalish RA, McHugh G, Granquist J, et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clinical Infectious Diseases 2001; 33(6):780-785.
104. Aguero-Rosenfeld ME, Nowakowski J, Bittker S, et al. Evolution of the serologic response to Borrelia burgdorferi in treated patients with culture-confirmed erythema migrans. Journal of Clinical Microbiology 1996; 34(1):1-9.
105. Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease): Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996;46(3):619-627.
106. Lanska DJ. Relevance of the antibody index to diagnose Lyme neuroborreliosis among seropositive patients. Neurology 2008;71(2):150; author reply 1.
107. Kaiser R. Variable CSF findings in early and late Lyme neuroborreliosis: A follow-up study in 47 patients. Journal of Neurology 1994;242(1):26-36.
108. Borchers AT, Keen CL, Huntley AC, Gershwin ME. Lyme disease: A rigorous review of diagnostic criteria and treatment. Journal of Autoimmunity 2015;57:82-115.
109. Gooskens J, Templeton KE, Claas EC, van Dam AP. Evaluation of an internally controlled real-time PCR targeting the ospA gene for detection of Borrelia burgdorferi sensu lato DNA in cerebrospinal fluid. Clinical Microbiology and Infection 2006; 12(9):894-900.
110. Nolte O. Nucleic acid amplification based diagnostic of Lyme (neuro-)borreliosis: lost in the jungle of methods, targets, and assays? The Open Neurology Journal 2012;6: 129-139.
111. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clinical Infectious Diseases 2006;43(9):1089-1134.